TV News LIES

Deadly yet easily preventable bloodstream infections continue to plague American hospitals because facility administrators fail to commit resources and attention to the problem, according to a survey of medical professionals released Monday.

An estimated 80,000 patients per year develop catheter-related bloodstream infections, or CRBSIs -- which can occur when tubes are inserted into a vein to monitor blood flow or deliver medication and nutrients are improperly prepared or left in longer than necessary. About 30,000 patients die as a result, according to the Centers for Disease Control and Prevention, accounting for nearly a third of annual deaths due to hospital-acquired infections in the United States.

Several little-known provisions of the new health care overhaul law take effect in coming months that could have a lasting impact on the nation's health care system.

They include eliminating co-payments for certain preventive services such as mammograms, giving the government more power to review health insurers' premium increases and allowing states to expand Medicaid coverage to low-income adults without children.

Here's a quick look at some of the changes that are occurring this year:

Two antibodies, VRC01 and VRC02, identified in HIV-infected blood, attach to the CD4 binding site of HIV and appear to prevent the virus from attaching to and infecting T cells, according to new research.

Peter D. Kwong, PhD, with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and colleagues reported the findings online today in Science.

After decades of pushing nations to surrender more power to Brussels, the European Union is about to throw in the towel on one highly contentious issue: genetically modified foods.

On Tuesday, the European Commission will formally propose giving back to national and local governments the freedom to decide whether to grow crops that many Europeans still call Frankenfoods.

Time and again, the scientists, doctors, drug makers and regulators who gathered Tuesday in Kansas City to talk about new cancer drugs spoke of the "valley of death." It's the long-cursed chasm between jaw-dropping breakthroughs in basic science — often unearthed at universities — and the manufacture of drugs that can battle your tumor.

(NYSE: PFE) announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor.